Raju Prasad
Stock Analyst at William Blair
(0.01)
# 4,661
Out of 5,090 analysts
10
Total ratings
20%
Success rate
-45.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Raju Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $5.02 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $9.61 | - | 1 | Feb 18, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $35.01 | - | 1 | Sep 2, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $46 | $5.05 | +810.89% | 1 | Feb 24, 2021 | |
| GBIO Generation Bio Co. | Initiates: Outperform | $450 | $5.36 | +8,295.52% | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $56.88 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $1.14 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $77.26 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.02
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.61
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $35.01
Upside: -
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: $46
Current: $5.05
Upside: +810.89%
Generation Bio Co.
Feb 24, 2021
Initiates: Outperform
Price Target: $450
Current: $5.36
Upside: +8,295.52%
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $56.88
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $77.26
Upside: -